Home › Companies › KTTA

Pasithea Therapeutics

Market cap $16.0M 36.8M shares (10-Q, Nov 12, 2026) × $0.434 close Nov 17, 2026

Most recent annual filing: 2026-03-30

Pipeline (4 active programs)

Discontinued (1)

Capital (as filed)

Cash
$41.2M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$4.5M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$41.2M cash per the update of Nov 13, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (5)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (5 calls)

Every verdict Biotech Distilled has published on Pasithea Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Buy core Pasithea Therapeutics (KTTA) - Scientific Deep Dive for PAS-004 and Pipeline Products Clean event-driven setup with elegant macrocycle chemistry, dilution-proof balance sheet through 1H 2028, and catalyst-rich 2H 2026 NF1-PN readout makes KTTA attractive for accumulation ahead of the data run.
  2. Buy core UPDATE: Pasithea Therapeutics (KTTA) - The Protocol Amendment Tax Macrocycle thesis intact with no safety signal or balance-sheet shock; 34.6% drawdown reflects timing re-pricing from protocol amendment rather than thesis breakage, so BUY is maintained despite degraded catalyst geometry.
  3. Buy core UPDATE: Pasithea Therapeutics (KTTA) - The Macrocycle Earns Its Keep Cancer trial interim confirms macrocycle PK advantage translates to chronic clinical tolerability with durable disease control in BRAF/MEK-pretreated patients, strengthening the thesis ahead of the Q4 NF1 interim.
  4. Buy core UPDATE: Pasithea Therapeutics (KTTA) - The Second Front Opens FDA IND clearance for a randomized placebo-controlled Phase 2 in NF1-cNF opens a second indication with no approved systemic competitor, playing directly to the macrocycle's chronic-tolerability edge and modestly increasing M&A appeal.
  5. Buy core UPDATE: Pasithea Therapeutics (KTTA) - The Marquee Event Lands on the Skin 15/15 cNF responders with 46% median reduction at Phase 2 doses in an indication with no approved systemic competitor strengthens the thesis, though a likely financing and Nasdaq compliance overhang prevent an upgrade.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (23)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jun 2, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

13 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)